53 of the 68 men based on the TB of the lesion (82.5%), 38 patients upgraded by the 12-core TRUS biopsy (60.3%). There were 27 patients upgraded on both the targeted lesion biopsy and the 12-core biopsy. On sub analysis 22 men had a PI-RADS 5 lesion(s). CDR was 21/22 patients (95.5%). The PI-RADS 5 lesions had an upgrade cancer detection rate of 90.5% (19/21 patients with cancer detected. 43 men had a PI-RADS 4 lesion(s), CDR was 33/43 patients (76.7%). PI-RADS 4 lesions had an upgrade cancer detection rate of 81.8% (27/33 patients with cancer detected). The 12-core systemic biopsy had a false negative rate of 39.3%. The biopsies of MRI targeted lesions of interest in total had a false negative rate of 17.5% compared to 9.5% false negative rate of PI-RADS 5 targeted lesions and 18.2% false negative rate of PI-RADS 4 targeted lesions.
INTRODUCTION AND OBJECTIVES:
To evaluate the evidence of ultrasound-MRI fusion target biopsy on PI-RADS score 3 prostate lesions METHODS: Between October, 2016 and July, 2018, 151 patients underwent ultrasound guided systemic prostate biopsy (12 cores) and ultrasound-MRI fusion target biopsy (2 to 8 cores) concurrently. PI-RADS scores were estimated by 2 experienced uroradiologists. Patients were categorized by PI-RADS scores into 4 groups: PI-RADS score 1-2, 3, 4 and 5. We analyzed the differences of prostate cancer detection rates among 4 groups. RESULTS: Age, prostate volume and number of target biopsy cores showed no significant differences among 4 groups. In PI-RADS score 3 group, mean positive core numbers and rate of positive cores were lower than systemic biopsy of total cohort ( p [ 0.02, 0.02, respectively). Overall cancer and clinically significant cancer detection rates of target biopsy in PI-RADS score 3 group (15.8 %, 14.0 %, respectively) were lower than systemic biopsy (43.7 %; p < 0.01, 35.1 %; p < 0.01, respectively). Overall cancer and clinically significant cancer detection rates of target biopsy on PI-RADS score 3 lesions were similar with PI-RADS score 1-2 lesions, but lower than PI-RADS score 5 lesions (74.3 %; p < 0.01, 71.4 %; p < 0.01, respectively).
CONCLUSIONS: Ultrasound-MRI fusion target biopsies on PI-RADS score 3 prostate lesions showed lower overall cancer and clinically significant cancer detection rates than systemic biopsy. There is a lack of evidence to support target biopsies on PI-RADS score 3 prostate lesions. A prospective randomized study with large sample size is needed. We retrospectively reviewed 127 patients who underwent multiparametric magnetic resonance imaging (mpMRI) and RCP for bladder cancer between November 2016 and January 2018. Incidence of PCa was identified and clinicopathologic characteristics were compared according to the presence of incidental PCa. Clinically significant PCa (CSC) was defined as Gleason score ! 7 and/or pathologic tumor stage ! pT3. All mpMRI findings were assessed with PI-RADSv2 RESULTS: Of the 127 patients, median prostate specific antigen (PSA) was 1.38ng/ml and PI-RADSv2 score 4-5 was detected in 34 (26.8%) patients. Incidental PCa was identified in 28 (22.0%) patients, of which 12 (42.9%) patients showed CSC. When patients were divided according to incidental PCa, PSA and PI-RADSv2 score were not significantly different (P [ 0.014 and P [ 0.226, respectively). However, PSA was not different but PI-RADASv2 score 4-5 was more frequently identified in patients with CSC (80.0% [8/10] vs 12.5% [2/16], P [ 0.005). In 13 patients with PSA ! 2.5ng/ml and PI-RADSv2 score 4-5, incidental PCa was diagnosed with 5 (38.5%) patients, of which CSC was detected in 4 (80.0%) patients.
CONCLUSIONS: After RCP, incidental PCa was found in 22% of patients. PI-RADSv2 score 4-5 was significantly associated with CSC. PI-RADSv2 might be used as a preoperative imaging tool to determine risk classification and to help counsel patients with regard to treatment decision
